SCHEMBL23733300

SCHEMBL23733300

CBCNC(=O)C1CCC(F)(F)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 4/20 0.39
HTR1A P08908 3/20 0.39
DRD2 P14416 3/20 0.39
DRD4 P21917 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
KMT2A Q03164 1/20 0.34
GSK3B P49841 2/20 0.34
DYRK1A Q13627 2/20 0.34
EPHX1 P07099 1/20 0.33
EPHX2 P34913 1/20 0.33
CCR5 P51681 5/20 0.33
WNT1 P04628 1/20 0.33
NAAA Q02083 1/20 0.33
CYP3A4 P08684 1/20 0.32
ADRA2A P08913 1/20 0.32
CYP2C9 P11712 1/20 0.32
KCNE1 P15382 1/20 0.32
OPRM1 P35372 1/20 0.32
KCNQ1 P51787 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22231128 0.77 CTH (0.40) KCNH2HTR1ADRD2DRD4SMN1; SMN2
SCHEMBL21703346 0.76 HTR1A (0.39) KCNH2HTR1ADRD2DRD4SMN1; SMN2
SCHEMBL2369715 0.76 HTR1A (0.39) KCNH2HTR1ADRD2DRD4SMN1; SMN2
SCHEMBL28271183 0.75 KCNH2 (0.43) KCNH2HTR1ADRD2DRD4SMN1; SMN2
SCHEMBL7929143 0.74 CHRNB2 (0.39) KCNH2HTR1ADRD2DRD4SMN1; SMN2
SCHEMBL31053494 0.71 HDAC8 (0.54) KCNH2HTR1ADRD2DRD4GSK3B
SCHEMBL27410245 0.71 SMN1; SMN2 (0.50) SMN1; SMN2KMT2AEPHX2CCR5
SCHEMBL18313483 0.70 GNAI3 (0.37) KCNH2HTR1ADRD2DRD4SMN1; SMN2
SCHEMBL15024277 0.70 EPHX2 (0.35) KCNH2HTR1ADRD2DRD4GSK3B
SCHEMBL22431439 0.69 EPHX2 (0.37) KCNH2HTR1ADRD2DRD4GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210238183-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA, INC. 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238183-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 KCNH2 1832/4885HTR1A 3419/4885DRD2 4770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.